A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150 mg: II. The comparison of bleeding patterns

Said, S.; Omar, K.; Koetsawang, Suporn; Kiriwat, Orawan; Srisatayapan, Yuwadee; Kazi, A.; Ajmal, Fozia; Wynter, H.; Pretnar-Darovec, A.; Benitez, Isidro; Cruz, J. de la; Apelo, R; Kovács, László; Koloszár, S; d’Arcangues, Catherine; Busca, B.; Hall, Peter; Machín, David

doi:10.1016/s0010-7824(87)80019-7

Cited by 42 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progestin only methods reduce MBL by inducing amenorrhea. Oral progestin only pills induced amenorrhea in 20% of women [ 53 ], but injectable medroxyprogesterone acetate (Depo-Provera) was reported to induce amenorrhea in 50% of women [ 54 ].…”

Section: Therapeutic Interventionsmentioning

confidence: 99%

Heavy menstrual bleeding diagnosis and medical management

Sriprasert

Pakrashi

Kimble

et al. 2017

Contracept Reprod Med

View full text Add to dashboard Cite

Heavy menstrual bleeding (HMB) is a common gynecological problem that has a significant impact on a woman’s quality of life and the activities of daily living. Due to the difficulty in accurately describing menstrual bleeding abnormalities using older terminology, the PALM-COEIN classification system of the Federation Internationale de Gynecologie et d’Obstetrique was proposed to describe and identify the etiology of abnormal endometrial bleeding. As there is no single pathway that is associated with HMB, there are several therapeutic interventions involving different molecular pathways to reduce HMB. This article will highlight the current evidence as it relates to the etiology of HMB as well as medical modalities of treatment.

show abstract

Section: Therapeutic Interventionsmentioning

confidence: 99%

Heavy menstrual bleeding diagnosis and medical management

Sriprasert

Pakrashi

Kimble

et al. 2017

Contracept Reprod Med

View full text Add to dashboard Cite

show abstract

“…No Pregnancy rates in the 27 studies of injectable contraceptives were low. Among 10 studies of DMPA for which the pregnancy rate was reported or could be calculated, rates ranged from 0.1 to 1.7 per 100 woman-years [83,87,89,94,[96][97][98][103][104][105][106]. Among studies of NET-EN, rates ranged from 0.3 to 6.6 per 100 woman-years [79,81,83,85,88,90,91,93,96,[101][102][103].…”

Section: Progestin (Dosage)mentioning

confidence: 99%